IPP Bureau
Lupin secures SBTi validation for emission reduction targets
By IPP Bureau - December 17, 2025
Glenmark secures exclusive multi-regional rights to Aumolertinib from Hansoh Pharma
By IPP Bureau - December 17, 2025
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Remedium Lifecare is now Supha Pharmachem
By IPP Bureau - December 17, 2025
The company shall process the change of name application with BSE Ltd. in due course
Lupin receives EIR from USFDA for Nagpur injectable facility
By IPP Bureau - December 17, 2025
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
AstraZeneca wins EU nod for self-administered lupus drug Saphnelo
By IPP Bureau - December 17, 2025
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Cynata completes patient enrollment for Phase 2 aGvHD clinical trial
By IPP Bureau - December 17, 2025
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
Bristol Myers Squibb launches AI-powered ‘Mosaic’ hub in Mumbai
By IPP Bureau - December 17, 2025
India plays a critical role in Bristol Myers Squibb’s global strategy
Revvity unveils AI-powered Signals Xynthetica to accelerate molecular and materials design
By IPP Bureau - December 17, 2025
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Merck KGaA launches ChemiSphere App to digitize lab workflows
By IPP Bureau - December 17, 2025
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses
By IPP Bureau - December 17, 2025
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Gujarat Kidney and Super Speciality to file IPO at Rs.108- Rs.114 per share
By IPP Bureau - December 17, 2025
The company operates a chain of mid-sized multi-speciality hospitals
Minghui Pharmaceutical gets FDA green light for Phase III trials of its therapy in thyroid eye disease
By IPP Bureau - December 17, 2025
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Ascletis Pharma reports positive Phase I results for oral IL-17 inhibitor
By IPP Bureau - December 17, 2025
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Vanda Pharmaceuticals seeks FDA nod for breakthrough psoriasis drug
By IPP Bureau - December 17, 2025
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
FDA nod to first oral single-dose treatment for gonorrhea
By IPP Bureau - December 16, 2025
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
